Dogwood Therapeutics, Inc. (DWTX) shareholders
Close on Nov 17, 2026Market cap $36.71MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CK Life Sciences Int'l., (Holdings) Inc. Joint filing with Sealbond Limited (67.80%), Conjoint Inc. (7.40%) | 28,763,331 | 75.20% | 13D (active) amendment | Oct 26, 2026 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 3,384,798 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 3,343,120 | 9.99% | 13G (passive) | Mar 31, 2026 |
| Sealbond Limited Joint filing with CK Life Sciences Int'l., (Holdings) Inc. (15.90%) | 211,383 | 15.90% | 13D (active) amendment | Mar 12, 2025 |
| Orca Capital AG | 115,790 | 6.10% | 13G (passive) | Mar 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DWTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 3,132,486 | 9.22% | $5.04M | −147,514 | 0.06% |
| Millennium Management LLC | 341,814 | 1.01% | $550.32K | New | 0.00% |
| Vanguard Capital Management LLC | 132,154 | 0.39% | $212.77K | – | 0.00% |
| Geode Capital Management, LLC | 88,298 | 0.26% | $142.16K | +8,864 | 0.00% |
| Vanguard Fiduciary Trust Co | 62,736 | 0.18% | $101.01K | – | 0.00% |
| BlackRock, Inc. | 28,546 | 0.08% | $45.96K | +28,516 | 0.00% |
| Northern Trust Corp | 23,779 | 0.07% | $38.28K | – | 0.00% |
| Citadel Advisors LLC | 11,742 | 0.03% | $18.91K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 3,093 | 0.01% | $4.98K | −4,974 | 0.00% |
| Morgan Stanley | 2,222 | 0.01% | $3.58K | New | 0.00% |
| UBS Group AG | 1,860 | 0.01% | $3.00K | −5,225 | 0.00% |
| Jones Financial Companies Lllp | 160 | 0.00% | $264 | New | 0.00% |
| Barclays PLC | 157 | 0.00% | $253 | New | 0.00% |
| Activest Wealth Management | 120 | 0.00% | $193 | – | 0.00% |
| Group One Trading, L.P. | 9 | 0.00% | $14 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 15 | 4M | 11.3% | 5 / 2 | 3 / 3 | 0M | 0M |
| Q1 2026 | 13 | 4M | 10.6% | 6 / 3 | 0 / 2 | 4M | 0M |
| Q4 2025 | 10 | 0M | 0.2% | 2 / 3 | 2 / 4 | 0M | 0M |
| Q3 2025 | 12 | 0M | 0.1% | 3 / 2 | 4 / 1 | 0M | 0M |
| Q2 2025 | 10 | 0M | 0.1% | 1 / 2 | 3 / 4 | 0M | 0M |
| Q1 2025 | 13 | 0M | 0.2% | 4 / 4 | 1 / 1 | 0M | 0M |
| Q4 2024 | 10 | 0M | 0.1% | 10 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held DWTX in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DWTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 132,154 | 0.39% | $212.77K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 57,163 | 0.17% | $96.61K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 26,624 | 0.08% | $42.86K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 13,059 | 0.04% | $22.07K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,294 | 0.01% | $3.88K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,892 | 0.01% | $3.05K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 880 | 0.00% | $1.49K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gregory Scott Duncan | CHIEF EXECUTIVE OFFICER, Director | 57,461 | 0.17% | Mar 6, 2026 |
| Roger Michael Gendreau | CHIEF MEDICAL OFFICER | – | – | Mar 6, 2026 |
| Ralph Grosswald | SVP OF OPERATIONS | – | – | Mar 6, 2026 |
| Angela Walsh | Chief Financial Officer | 3,000 | 0.01% | Mar 6, 2026 |
| Inc. Conjoint | Director, 10% owner | 24,664,971 | 72.56% | Oct 27, 2026 |
| Ltd Sealbond | Director, 10% owner | 28,763,331 | 84.62% | Oct 27, 2026 |
| Life Sciences Intl (Holdings) Inc CK | Director, 10% owner | – | – | Oct 27, 2026 |
| David R. Keefer | Director | 12,808 | 0.04% | Jun 17, 2026 |
| John C. Thomas | Director | 1,000 | 0.00% | Jun 17, 2026 |
| Richard James Whitley | Director | 700 | 0.00% | Jun 17, 2026 |
| La Rosa Abel De | Director | 4,000 | 0.01% | Jun 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ltd Sealbond Director, 10% owner | Oct 26, 2026 | Award | +4,098,360 | $1.22 | $5.00M | 25,920,693 |
| Inc. Conjoint Director, 10% owner | Nov 21, 2025 | Conversion | +21,610,950 | – | – | 21,822,333 |
| Inc. Conjoint Director, 10% owner | Nov 21, 2025 | Conversion | +2,842,638 | – | – | 2,842,638 |
| William Pridgen Director | Aug 21, 2023 | Buy | +15,335 | $1.30 | $19.94K | 52,045 |
| Gregory Scott Duncan CHIEF EXECUTIVE OFFICER, Director | Aug 17, 2023 | Buy | +25,000 | $1.25 | $31.25K | 57,461 |
| Richard James Whitley Director | Dec 8, 2022 | Sale | −1,800 | $0.26 | $468 | 700 |
| Gregory Scott Duncan CHIEF EXECUTIVE OFFICER, Director | May 23, 2022 | Buy | +7,500 | $4.52 | $33.90K | 32,461 |
| Angela Walsh SVP OF FINANCE | May 23, 2022 | Buy | +2,000 | $4.58 | $9.16K | 3,000 |
| Richard James Whitley Director | May 18, 2022 | Buy | +500 | $4.53 | $2.27K | 2,500 |
| William Pridgen Director | May 18, 2022 | Buy | +241 | $4.50 | $1.08K | 36,710 |
| William Pridgen Director | May 17, 2022 | Buy | +13,450 | $4.38 | $58.91K | 36,469 |
| William Pridgen Director | Mar 29, 2022 | Buy | +600 | $4.94 | $2.96K | 23,019 |
| William Pridgen Director | Mar 23, 2022 | Buy | +2,197 | $5.46 | $12.00K | 22,419 |
| William Pridgen Director | Jan 27, 2022 | Buy | +4,180 | $5.98 | $25.00K | 18,722 |
| La Rosa Abel De Director | Jan 7, 2022 | Buy | +4,000 | $5.90 | $23.60K | 4,000 |
| Richard James Whitley Director | Jan 6, 2022 | Buy | +1,800 | $5.72 | $10.30K | 2,000 |
| David R. Keefer Director | Jan 4, 2022 | Buy | +5,000 | $5.80 | $29.00K | 5,000 |
| John C. Thomas Director | Jan 4, 2022 | Buy | +1,000 | $5.65 | $5.65K | 1,000 |
| William Pridgen Director | Jan 3, 2022 | Buy | +2,215 | $5.43 | $12.03K | 14,542 |
| Richard James Whitley Director | Dec 23, 2021 | Buy | +200 | $5.73 | $1.15K | 200 |
| William Pridgen Director | Dec 21, 2021 | Buy | +8,827 | $5.66 | $49.96K | 12,327 |
| Gregory Scott Duncan CHIEF EXECUTIVE OFFICER, Director | Dec 21, 2021 | Buy | +5,000 | $5.52 | $27.60K | 24,961 |
| William Pridgen Director | Jul 7, 2021 | Buy | +942 | $6.32 | $5.95K | 710,734 |
| Gregory Scott Duncan Chief Executive Officer, Director | Apr 6, 2021 | Buy | +382 | $6.36 | $2.43K | 19,961 |
| Gregory Scott Duncan Chief Executive Officer, Director | Apr 5, 2021 | Buy | +15,675 | $6.17 | $96.71K | 19,579 |
| Gregory Scott Duncan Chief Executive Officer, Director | Apr 5, 2021 | Buy | +15,675 | $6.17 | $96.71K | 19,579 |
| William Pridgen Director | Jan 29, 2021 | Buy | +3,500 | $7.47 | $26.15K | 3,500 |
| Angela Walsh VP of Finance | Jan 28, 2021 | Buy | +1,000 | $7.30 | $7.30K | 1,000 |
| David R. Keefer Director | Jan 28, 2021 | Option exercise | +1,602 | $7.80 | $12.50K | 7,808 |
| William Pridgen Director | Jan 28, 2021 | Option exercise | +801 | $7.80 | $6.25K | 727,993 |
| Gregory Scott Duncan Chief Executive Officer, Director | Jan 6, 2021 | Option exercise | +801 | $7.80 | $6.25K | 3,904 |
| William Pridgen Director | Dec 17, 2020 | Buy | +1,500 | $11.98 | $17.97K | 727,192 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Dogwood Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,762 shares on Oct 14, 2026 over the last 90 days.
See a number that looks wrong?